Literature DB >> 8389806

A genetically determined host factor controlling susceptibility to encephalomyocarditis virus-induced diabetes in mice.

Y Kang1, J W Yoon.   

Abstract

Levels of insulin mRNA in pancreata from SJL/J male mice susceptible to encephalomyocarditis (EMC)-D virus-induced diabetes started to decrease rapidly 24 h after injection with EMC-D virus and only a trace remained 72 h after injection. In contrast, insulin mRNA in pancreata from C57BL/6J male mice resistant to EMC-D virus-induced diabetes did not show any significant changes 0 to 96 h after injection. EMC-D viral RNA in pancreata from SJL/J mice started to increase rapidly 24 h after injection, reached its peak at 48 h and then decreased gradually. In contrast, EMC-D viral RNA in pancreata from C57BL/6J mice was undetectable except for the 24 and 48 h points after injection. EMC-D virus could bind readily to freshly isolated beta cells from SJL/J mice but scarcely bound to beta cells from C57BL/6J mice. In contrast, there was no significant difference between SJL/J and C57BL/6J mice in binding of EMC-D virus to their cultured beta cells. The rate of EMC-D viral attachment to beta cells from C57BL/6J mice increased significantly during the first 24 h culture period and reached the same rate of attachment as that seen for beta cells from SJL/J mice. This suggests that viral receptors on the beta cells derived from strains of mice resistant to EMC virus-induced diabetes are not expressed in vivo, but are expressed during cell culture, rendering the beta cells susceptible to EMC viral infection. On the basis of our previous and present observations, we conclude that a genetic factor controlling susceptibility to EMC-D virus-induced diabetes may operate by modulating the expression of viral receptors on the beta cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389806     DOI: 10.1099/0022-1317-74-6-1207

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Distribution of viral RNA in the spinal cord of DBA/2 mice developing biphasic paralysis following infection with the D variant of encephalomyocarditis virus (EMC-D).

Authors:  M Takeda; R Miura; K Shiota; K Hirasawa; M J Lee; S I Itagaki; K Doi
Journal:  Int J Exp Pathol       Date:  1995-12       Impact factor: 1.925

2.  Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue.

Authors:  N D Borson; C Paul; X Lin; W K Nevala; M A Strausbauch; M Rodriguez; P J Wettstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Identification and characterization of the cell surface 70-kilodalton sialoglycoprotein(s) as a candidate receptor for encephalomyocarditis virus on human nucleated cells.

Authors:  Y M Jin; I U Pardoe; A T Burness; T I Michalak
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Prevention of encephalomyocarditis virus-induced diabetes in mice by inhibition of the tyrosine kinase signalling pathway and subsequent suppression of nitric oxide production in macrophages.

Authors:  K Hirasawa; H S Jun; H S Han; M L Zhang; M D Hollenberg; J W Yoon
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 5.  The encephalomyocarditis virus.

Authors:  Margot Carocci; Labib Bakkali-Kassimi
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

6.  Reduced Tyk2 gene expression in β-cells due to natural mutation determines susceptibility to virus-induced diabetes.

Authors:  Kenichi Izumi; Keiichiro Mine; Yoshitaka Inoue; Miho Teshima; Shuichiro Ogawa; Yuji Kai; Toshinobu Kurafuji; Kanako Hirakawa; Daiki Miyakawa; Haruka Ikeda; Akari Inada; Manami Hara; Hisakata Yamada; Koichi Akashi; Yoshiyuki Niho; Keisuke Ina; Takashi Kobayashi; Yasunobu Yoshikai; Keizo Anzai; Teruo Yamashita; Hiroko Minagawa; Shuji Fujimoto; Hironori Kurisaki; Kazuya Shimoda; Hitoshi Katsuta; Seiho Nagafuchi
Journal:  Nat Commun       Date:  2015-04-07       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.